Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8633789 | 0.91 | CYP1A2 (0.52) | SMN1; SMN2TSHRCASP1RAB9ANPC1 | |
| SCHEMBL5793042 | 0.88 | RAB9A (0.47) | SMN1; SMN2TSHRCASP1RAB9ANPC1 | |
| SCHEMBL3138767 | 0.81 | CES2 (0.54) | SMN1; SMN2TSHRRAB9ANPC1MAPT | |
| SCHEMBL522683 | 0.80 | SRD5A2 (0.74) | SMN1; SMN2TSHRCASP1RAB9ANPC1 | |
| SCHEMBL28668332 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRCASP1RAB9ANPC1 | |
| SCHEMBL9593190 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRCASP1RAB9ANPC1 | |
| SCHEMBL29350361 | 0.80 | SRD5A2 (0.74) | SMN1; SMN2TSHRCASP1RAB9ANPC1 | |
| Benzoic Acid SCHEMBL8021112 | 0.79 | TSHR (0.78) | SMN1; SMN2TSHRCASP1RAB9ANPC1 | |
| SCHEMBL9749593 | 0.79 | CES1 (0.62) | SMN1; SMN2TSHRCASP1RAB9ANPC1 | |
| SCHEMBL33952 | 0.78 | ALDH1A1 (0.56) | SMN1; SMN2TSHRRAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3431490-B1 | CHEMICAL COMPOUNDS FOR USE AS DIAGNOSTIC MARKERS OF INFLAMMATION AND NEOPLAMS, THE METHOD FOR SYNTHESIS OF THE CHEMICAL COMPOUNDS, DIAGNOSTIC KIT FOR USE IN DIAGNOSIS OF INFLAMMATORY PROCESSES AND EPITHELIAL NEOPLASMS AND IN VITRO DIAGNOSTIC METHOD OF INFLAMMATORY PROCESSES AND EPITHELIAL NEOPLASMS | UNIV GDANSKI (PL) | 2020-03-11 | — | — | EP | claimed |
| WO-2020017984-A1 | CHEMICAL COMPOUNDS FOR USE AS DIAGNOSTIC MARKERS OF INFLAMMATION AND NEOPLASMS | UNIWERSYTET GDANSKI (PL) | 2020-01-23 | — | — | WO | claimed |
| EP-3431490-A1 | CHEMICAL COMPOUNDS FOR USE AS DIAGNOSTIC MARKERS OF INFLAMMATION AND NEOPLAMS, THE METHOD FOR SYNTHESIS OF THE CHEMICAL COMPOUNDS, DIAGNOSTIC KIT FOR USE IN DIAGNOSIS OF INFLAMMATORY PROCESSES AND EPITHELIAL NEOPLASMS AND IN VITRO DIAGNOSTIC METHOD OF INFLAMMATORY PROCESSES AND EPITHELIAL NEOPLASMS | Uniwersytet Gdanski (PL) | 2019-01-23 | — | — | EP | claimed |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240199701-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-20 | — | — | US | disclosed |
| CN-118159549-A | Immunomodulators | 百时美施贵宝公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024112809-A2 | CELL-PENETRATING PEPTIDES, CONJUGATES THEREOF, AND METHODS OF THEIR USE | PEPGEN INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| CN-118076623-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024102752-A1 | SMALL MOLECULE MODULATORS OF PAR2 AND USES THEREOF | PARMEDICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11952379-B2 | Small molecule modulators of PAR2 and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-04-09 | — | — | US | disclosed |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-6617309-B2 | For therapy and prophylaxis of hepatitis C viral infection | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-09 | — | — | US | disclosed |
| EP-1242363-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| US-20020032175-A1 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-03-14 | — | — | US | disclosed |
| EP-0932617-B1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMA (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1136498-A1 | Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease | Vertex Pharmaceuticals Incorporated (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6265380-B1 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED | 2001-07-24 | — | — | US | disclosed |
| WO-2001046125-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| EP-0932617-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998017679-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199701-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | SMN1; SMN2 4385/4885TSHR 1050/4885CASP1 1220/4885 |
| US-11952379-B2 | Small molecule modulators of PAR2 and uses thereof | F2RL1, F2R, TBXA2R | SMN1; SMN2 4378/4885TSHR 2256/4885CASP1 829/4885 |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | SMN1; SMN2 4722/4885TSHR 3853/4885CASP1 3578/4885 |
| US-20020032175-A1 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | HPN, PRSS1, PRSS3 | SMN1; SMN2 3883/4885TSHR 4795/4885CASP1 359/4885 |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, MTOR, FKBP14 | SMN1; SMN2 4628/4885TSHR 4022/4885CASP1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.